FDA: Paxil Linked to Birth Defects

	Tweet

The FDA warned doctors today that preliminary results implicate the antidepressant Paxil (paroxetine) with an increased risk of birth defects.

The FDA informed doctors that results of new studies suggest that Paxil use during the first trimester increases the risk of congenital heart defects in the developing fetus.

The FDA advised physicians to discuss the potential risk of birth defects with women taking Paxil who plan to become pregnant or who are in the first trimester of pregnancy. Doctors should consider discontinuing Paxil in these patients and switching to another antidepressant if indicated. In some patients, the benefits of continuing Paxil may be greater than the potential risk to the fetus, the FDA said.

In general, however, the FDA advised that the drug should not be taken during pregnancy. But women who are taking Paxil should consult their physicians before stopping the drug. The FDA action was prompted by results of two studies that showed that women who took Paxil during the first three months of pregnancy were about one and a half to two times as likely to have a baby with a heart defect as women who received other antidepressants or women in the general population. The most common defects were atrial and Ventricular septal defects that ranged in severity from minor, self-resolving defects to serious defects that required surgical repair.

The FDA said that in one of the studies, the risk of heart defects in babies whose mothers had taken Paxil early in pregnancy was about 2%, compared with a 1% expected risk in the general population. In the other study, the risk of heart defects in babies whose mothers had taken Paxil in the first three months of pregnancy was 1.5% compared to 1% risk for women taking other antidepressants.

The FDA said it asked Paxil’s manufacturer, GlaxoSmithKline, to change the drug’s label to upgrade the pregnancy warning from a category C to a category D, a higher level warning. The company changed the label two months ago to add data from one of the studies. The latest label change reflects data from both studies, the FDA said.

RELATED STORIES:
SSRIs associated with severe violence in a small number of individuals   Antidepressants may affect immune system   Do We Really Know the Truth About Antidepressants?   New findings on antidepressants during pregnancy are reason for caution, not alarm   As Antidepressants Begin to Work, Hopelessness Can Linger   When one antidepressant fails, another may work   Daily Use of Antidepressants Associated With Increased Risk of Fracture in Older Adults   European drug watchdog backs Prozac for children   Wellbutrin plus reward helps cocaine users cut back   Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents   SSRIs and cardiovascular health   Zoloft does not prevent post-stroke depression   Antidepressant withdrawal symptoms seen in babies   Prozac counters emotional turmoil after stroke   Antidepressant suicide risk up five times for seniors

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]